Shirakawa M1, Kanamoto Y1, Nagaoka H1, Honda H2, Bando H3*
1Shishikui Clinic, Kaiyo, Kaifu-gun, Tokushima, Japan
2Minami Hospital, Minami, Kaifu-gun, Tokushima, Japan
3Tokushima University,/ Medical Research, Tokushima, Japan
Corresponding Author: Hiroshi Bando, MD, PhD, FACP
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 26 March 2019; Accepted date: 08 April 2019; Published date: 16 April 2019
Recent treatment for type 2 diabetes mellitus (T2DM) has included glucagon-like peptide-1 receptor agonist (GLP-1 RA), indicating clinical efficacy for better glucose variability. Subjects were seven patients with T2DM associated with the obese tendency. Their average age was 63.8 ± 21.7 years old (5 males, 2 females) who received a new administration of GLP-1 RA (Mean ± standard deviation). For GLP-1 RA, dulaglutide (TRULICITY R, single-dose pen) was administered by subcutaneous injection 0.75 mg once a week. Basal data at 0 month revealed that body weight 76.0 ± 11.6 kg, body mass index (BMI) 29.2 ± 11.6, blood C-peptide immunoreactivity (CPR) 2.68 ± 0.49 ng/mL, respectively. After the intervention of dulaglutide, decreased value of BMI for 3 and 6-9 months was 0.78 ± 0.45 and 1.16 ± 0.85, and HbA1c for 3 and 6-9 months was 1.60 ± 1.52% and 2.01 ± 1.44%, respectively. Though these cases have various complications besides T2DM, they showed clinical effects of weight reduction and lowering blood glucose. Diabetic treatment for current cases would suggest that GLP-1 RA would be effective in various situations such as a super-aged patient, medical practice in the remote area, family care and visiting nursing.
Citation: Shirakawa M, Kanamoto Y, Nagaoka H, et al., “Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA)”. Asp Biomed Clin Case Rep, vol.2, no.s1: 38-46, 2019.
Copyright © 2019 Shirakawa M, Kanamoto Y, Nagaoka H, et al., This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Key Words: Low Carbohydrate Diet (LCD); GLP-1 Receptor Agonist (GLP-1 RA); Dulaglutide; Type 2 Diabetes Mellitus (T2DM); Dipeptidyl Peptidase-4 (DPP-4) Inhibitor; Intestine Secretion Insulin (INCRETIN)
Abbreviation: Glucagon-Like Peptide-1 (GLP-1); GLP-1 Receptor Analogue (GLP-1 RA); Calorie Restriction Diet (CRD); Low Carbohydrate Diet (LCD); Mediterranean Diet (MD); Gastric Inhibitory Polypeptide (GIP); Type2 Diabetes Mellitus (T2DM); Dipeptidyl Peptidase-4 (DPP-4) ; Fasting Blood Glucose (FBG)